3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 1/2
3
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
18
Carcinoma, Non-Small-Cell Lung
10
Carcinoma, Renal Cell
9
Kidney Neoplasms
4
Stomach Neoplasms
3
Mesothelioma
3
Lung Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Carcinoma, Hepatocellular
3
Skin Neoplasms
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Various Advanced Cancer
1
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Recurrence
1
Non-Small Cell Lung Cancer Metastatic
1
Neoplasms
1
Melanoma, Cutaneous Malignant
1
Lymphatic Metastasis
1
Interventions
Sorafenib
8
durvalumab
4
Cisplatin
4
Gemcitabine
3
Ethiodized Oil
3
Doxorubicin
3
Chemotherapy, Adjuvant
3
Bevacizumab
3
tremelimumab
2
sodium thiosulfate
2
phosphomannopentaose sulfate
2
Watchful Waiting
2
Talaporfin
2
Radiofrequency Ablation
2
Oxaliplatin
2
Nivolumab
2
Folfox protocol
2
Celecoxib
2
Capecitabine
2
Analgesia, Patient-Controlled
2
seocalcitol
1
parecoxib
1
nolatrexed
1
linifanib
1
lenvatinib
1
ferumoxides
1
ferric carboxymaltose
1
contrast agent BR1
1
cabozantinib
1
brivanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Liver Neoplasms
×
Ipilimumab
×
Clear all
NCT04340193
2024-11-26
CheckMate 74W
Bristol-Myers Squibb
Phase 3
Completed
26 enrolled
15 charts